

Review on Virosomes: As a Drug Delivery Carriers

Dipali Katare, Bilal Sufi, Jayesh D. Nil, Ashwini Ashtankar
New Montfort Institute of Pharmacy, Ashti, Wardha, Maharashtra, India
kataredipali29@gmail.com

Abstract: *Since the last era, some revolutionary advances in drug delivery technologies have been observed in the realization of targeted drug delivery or targeted drug action at the site. The prospects for the use of biological molecules nanoparticles such as virosomes as drugs are motivating research and development areas that show the targeted fusion effects with the targeted fusion effects by target cells. Virosomes are biocompatible, biodegradable, non-toxic and non-autoimmunogeneous viral species and are new carriers and drug delivery systems for vaccines and cell delivery of active macromolecules. Virosomes are biomimetic nanoparticle drug delivery systems that contain active macromolecules in a virus coat made of lipid membranes. The administration of virosomes takes place through various methods such as the intramuscular (IM), intravenous (IV), intravascular, subcutaneous (SC), oral and inhalation routes. The research paper focuses on the structure, components, types and formulations of virosomes, the mechanism of action and applications of viral genes, and available commercial formulations.*

Keywords: Virosomes, Drug delivery, Genes, Virus, Structure, mechanism of action, preparation etc

REFERENCES

- [1]. Kalra, N., et al. 2013. Virosomes : As a Drug Delivery Carrier. American Journal of Advanced Drug Delivery, 1(1):29–35.
- [2]. Almeida JD, Brand CM, Edwards DC, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet. 1975;2:899–901.
- [3]. Bhattacharya Sanjib, Muzumder Bhaskar. Virosomes A Novel Strategy for Drug Delivery and Targeting. Biopharm International, 2011; volume 2011 Supplement (issue1).
- [4]. Idris N, Chilkawar R, Nanjwade B, Srichana T, Shafioul A. Nanotechnology Based Virosomal Drug Delivery Systems. Journal of Nanotechnology and Materials Science 2014; 1(1):27- 35.
- [5]. Morein, B., et al. 1978. Effective subunit vaccines against an enveloped animal virus. Nature, 276(5689):715–718.
- [6]. Zurbriggen, R. 2003. Immunostimulating reconstituted influenza virosomes. Vaccine, 21(9):921– 924.
- [7]. Uchida, T. 1979. Reconstitution of lipid vesicles associated with HVJ (Sendai virus) spikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin. Journal of Cell Biology, 80(1):10–20.
- [8]. Kaneda, Y. 2002. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Molecular Therapy, 6(2):219–226.
- [9]. Dr. Shaikh Siraj N, Shahid Raza, Mohd. Aslam Ansari, Dr. G.J. Khan, Siddiqi Hifzurrahman MD Athar. Overview on virosomes as a novel carrier for drug delivery. Journal of Drug Delivery & Therapeutics, 2018; 8(6-s):429-434.
- [10]. Kalra Naresh, Dhanya V, Saini Vineeta, Dr.Jeyabalan G. Virosomes: As a Drug Delivery Carrier. American Journal of Advanced Drug Delivery, 2013; ISSN-2321-547X: 029-035.
- [11]. Sarkar D.P, Ramani K, Tyagi S.K. Targeted Gene Delivery by Virosomes. Methods in Molecular Biology, 2002; 199: 163.
- [12]. Kumar V.V, Singh R.S, Chaudhari A. Cationic Transfection Lipids in Gene Therapy: Successes, setbacks, challenges and promises. Current Medicinal Chemistry, 2003; 10: 1297-1306.
- [13]. Naresh Kalra et al, Virosomes: As a Drug Delivery Carrier, American Journal of Advanced Drug Delivery, Date of Acceptance- 02/05/2013.

- [14]. Kumari A, Singla R, Guliani A, Yadav SK. Nanoencapsulation for Drug Delivery. EXCLI Journal 2014; 13:265-286.
- [15]. Kapoor D, Vyas RB, Lad C, Patel M. Amultipurpose and novel carrier for drug delivery and targeting virosomes. Journal of Drug Delivery & Therapeutics 2013; 3(5):143-147
- [16]. Priyanka Rathore et al, VIROSOMES: A NOVEL VACCINATION TECHNOLOGY, INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2012; Vol. 3(10): 3591-3597
- [17]. Bungener L, Huckriede A, Wilschut J, Daemen T. Virosomes as a vaccine delivery system. In: 14th European Immunology Meeting (EFIS 2000). Medimond Publishing Company. 2000:845-50
- [18]. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, Wilschut J. The virosome concept for influenza vaccines. Vaccine 2005; 23(S1):S26–38.
- [19]. Felnerova D, Viret JF, Glück R, Moser C: Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15:518–29
- [20]. Harandi, A., Medagliani, D. 2010. Mucosal Adjuvants. Current HIV research, 8(4):330–335.
- [21]. Shaikh SN, Raza S, Ansari MA, Khan GJ, Athar SH. Overview on virosomes as a novel carrier for drug delivery. J Drug Deliv Ther. 2018;8(6-s):429-34.
- [22]. Mufeeda P et al, VIROSOMES; A NOVAL APPROACH IN NOVAL DRUG DELIVERY SYSTEM:
- [23]. A REVIEW, International Journal of Modern, 2020, 4(1), 132-137
- [24]. Nagi F. et al, Nanotechnology Based Virosomal Drug Delivery Systems, Journal of Nanotechnology and Materials Science, Accepted date: Dec 11, 2014.